F3 and cancer: Over 5% of people presenting with a first VTE are subsequently diagnosed with cancer within the ensuing year[4,5] and several studies have indicated that cancer risk may be elevated over the longer term for people with a history of VTE.[6–9] Experiments in mice indicate that pro-thrombotic proteins, including tissue factor and fibrinogen, facilitate tumour growth, survival and metastasis.[10,11] However, observational studies examining whether treatment with antiplatelet or anticoagulant medication reduces risks of cancer have shown conflicting results.[12–14]